Subscribers,

We first introduced you to Anixa Biosciences, Inc recently when it announced blockbuster news that the Company, along with OntoChem GmbH, had identified its first therapeutic candidate against Covid-19, and has advanced the compound into biological testing. 

ANIX proceeded to jump 30% on the news.

According to ANIX, this is the first therapeutic candidate identified from the strategic partnership recently established by Anixa and OntoChem to evaluate over 1.2 billion molecules through an in silico study to identify potential therapies for patients infected by SARS-CoV-2, the virus that causes Covid-19 (https://ir.anixa.com/press-releases/detail/947/). Anixa believes that drugs targeting the molecular biology of SARS-CoV-2 will produce more powerful medicines than the drugs currently being evaluated in trials, most of which were repurposed from other diseases.

This first compound is expected to disrupt the interaction of the virus's endoribonuclease with a host human protein that is necessary for the virus to replicate upon infection. Disrupting this protein-protein interaction is expected to dramatically reduce or eliminate the virus's ability to cause disease. The biological testing will initially determine how well this compound binds to the endoribonuclease, and then how well this translates into reducing viral replication in human host cells.

Dr. Amit Kumar, President and CEO of Anixa Biosciences stated, "While we continue to screen the full libraries of compounds, we have already identified a potential drug to be evaluated in biological testing against SARS-CoV-2. This is in contrast with most existing efforts which are repurposed compounds. With the urgency of the Covid-19 pandemic, we are pleased that this program is moving forward at such a rapid pace. As the study continues, we expect to identify several additional drug candidates that will be evaluated biologically, after which we will choose which compound to advance into animal testing. If all goes as planned, drug discovery activities could be completed within six months."

"We are excited to have quickly identified our first 'hit' compound, and we anticipate this program will continue to advance rapidly," stated Dr. Lutz Weber, CEO of OntoChem. "To our knowledge, this project is screening the largest number of compounds with the broadest chemical diversity ever tried against SARS-CoV-2. Our expectation is that we will identify multiple candidate compounds through our in silico discovery effort while in parallel evaluating the most promising candidates in biological assays."

Dr. Kumar continued, "Since SARS-CoV-2 has, in a matter of months, caused a global pandemic and induced tremendous economic disruptions, we intend to provide frequent updates on our progress."

You can read in full at https://finance.yahoo.com/news/anixa-biosciences-ontochem-announce-discovery-104500443.html

In late April, ANIX made another exciting announcement of the publication of a peer-reviewed journal article in Biomarker Insights.  The article, entitled "Detecting Prostate Cancer Using Pattern Recognition Neural Networks with Flow Cytometry-Based Immunophenotyping in At-Risk Men," supports the use of Anixa's Cchek™ early cancer detection technology as a tool to improve prostate cancer detection and reduce unnecessary biopsies.

Cchek™ is an artificial intelligence (AI)-driven platform developed as a simple blood test to detect solid tumors by screening for the body's immune response to the presence of a malignancy.  The technology uses flow cytometry of white blood cells and AI to identify tumor-bearing patients.

You can read this press release in full at https://finance.yahoo.com/news/anixa-biosciences-announces-publication-peer-110000978.html

You can also watch Dr Amit Kumar, President and CEO of Anixa Biosciences discuss these treatments for TD Ameritrade at https://tdameritradenetwork.com/video/rB4AoXHUFCyBceX48XEFIw


ANIX is sure to continue to excite the market and investors alike. Make sure you continue to keep a close eye on ANIX.



All the best.

SmallCapMomo.com

picks@smallcapmomo.com

Remember our key trading rules when trading. Capital preservation is key. Keep your stops tight, and if things don't go your way, cut your losses and look for another opportunity.